Abstract
Purpose
Bladder cancer (BC) ranks first in the incidence of urogenital tumors in China and second only to prostate cancer in the West. This study will clarify the roles and mechanism of lncRNA GHET1 in chemotherapeutic resistance of BC to Gemcitabine.
Methods
The expression of GHET1 was examined using real-time quantitative PCR. Cell Counting Kit-8 assay was applied to analyze cell proliferation and Gemcitabine sensitivity. Cell apoptosis was detected using Annexin V-FITC/PI double-stained flow cytometry. The expression of ABCC1 protein was examined using Western blotting.
Results
Firstly, the expression of GHET1 was up-regulated in BC, its high expression was relevant to high grade and muscle invasion of BC patients. Secondly, high expression of GHET1 was related to low Gemcitabine sensitivity of BC patients, and GHET1 was highly expressed in Gemcitabine-resistant BC cell lines. Thirdly, knockdown of GHET1 decreased the IC50 of Gemcitabine in Gemcitabine-resistant BC cell lines and advanced the Gemcitabine-induced cytotoxicity; GHET1 promoted Gemcitabine resistance in BC. Finally, knockdown of GHET1 also inhibited the expression of ABCC1 protein in Gemcitabine-resistant BC cells.
Conclusions
High expression of GHET1 was related with the low sensitivity to Gemcitabine of BC; GHET1 contributed to chemotherapeutic resistance to Gemcitabine in BC through up-regulating ABCC1 expression. Our findings are helpful to expound the molecular mechanism of chemotherapeutic resistance in BC.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132
Chen W, Zheng R, Zeng H, Zhang S (2016) The incidence and mortality of major cancers in China, 2012. Chin J Cancer 35(1):73
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108
Buttigliero C, Tucci M, Vignani F, Scagliotti GV, Di Maio M (2017) Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treat Rev 54:1–9
Drayton RM, Catto JW (2012) Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther 12(2):271–281
Pan J, Li X, Wu W, Xue M, Hou H, Zhai W, Chen W (2016) Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett 382(1):64–76
Liu Z, Xie D, Zhang H (2018) Long noncoding RNA neuroblastoma-associated transcript 1 gene inhibits malignant cellular phenotypes of bladder cancer through miR-21/SOCS6 axis. Cell Death Dis 9(10):1042
Luo Z, Pan J, Ding Y, Zhang YS, Zeng Y (2018) The function and clinical relevance of lncRNA UBE2CP3-001 in human gliomas. Arch Med Sci 14(6):1308–1320
Hu X, Hong Y, Shang C (2019) Knockdown of long non-coding RNA SNHG5 inhibits malignant cellular phenotypes of glioma via Wnt/CTNNB1 signaling pathway. J Cancer 10(5):1333–1340
Huang Y, Du J, Mi Y, Li T, Gong Y, Ouyang H, Hou Y (2018) Long non-coding RNAs contribute to the inhibition of proliferation and EMT by pterostilbene in human breast cancer. Front Oncol 8:629
Wang XM, Liu Y, Fan YX, Liu Z, Yuan QL, Jia M, Geng ZS, Gu L, Lu XB (2018) LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther 19(7):590–597
Saeinasab M, Bahrami AR, González J, Marchese FP, Martinez D, Mowla SJ, Matin MM, Huarte M (2019) SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF. J Exp Clin Cancer Res. 38(1):172
An Q, Zhou L, Xu N (2018) Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother 103:415–420
Zhang H, Guo Y, Song Y, Shang C (2017) Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother Pharmacol 79(1):49–55
Guo Y, Zhang H, Xie D, Hu X, Song R, Zhu L (2018) Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway. Cancer Manag Res 10:4371–4380
Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi K, Gu Y, Fang G (2014) Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J 281(3):802–813
Han M, Wang Y, Gu Y, Ge X, Seng J, Guo G, Zhang X, Zhao Y, Dou D (2019) lncRNA GHET1 knockdown suppresses breast cancer activity in vitro and in vivo. Am J Transl Res 11(1):31–44
Ni W, Luo L, Zuo P, Li RP, Xu XB, Wen F, Hu D (2018) lncRNA GHET1 down-regulation suppresses the cell activities of glioma. Cancer Biomark 23(1):9–22
Xia Y, Yan Z, Wan Y, Wei S, Bi Y, Zhao J, Liu J, Liao DJ, Huang H (2018) Knockdown of long noncoding RNA GHET1 inhibits cell-cycle progression and invasion of gastric cancer cells. Mol Med Rep 18(3):3375–3381
Li LJ, Zhu JL, Bao WS, Chen DK, Huang W, Weng ZL (2014) Long noncoding RNA GHET1 promotes the development of bladder cancer. Int J Clin Exp Pathol 7(10):7196–7205
Zhang X, Bo P, Liu L, Zhang X, Li J (2017) Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharmacother 92:580–585
Li X, Wang H, Wang J, Chen Y, Yin X, Shi G, Li H, Hu Z, Liang X (2016) Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. BMC Cancer 16:578
Liu Z, Zhang H (2017) LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. Oncotarget 8(38):64273–64282
Xie D, Zhang H, Shang C (2018) Long non-coding RNA CDKN2B antisense RNA 1 gene inhibits Gemcitabine sensitivity in bladder urothelial carcinoma. J Cancer 9(12):2160–2166
Huo JF, Chen XB (2019) Long noncoding RNA growth arrest-specific 5 facilitates glioma cell sensitivity to cisplatin by suppressing excessive autophagy in an mTOR-dependent manner. J Cell Biochem 120(4):6127–6136
Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, Jin Y, Zou C, Chen Y, Wang G, Gao X, Wang X (2018) Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis 9(12):1149
Zhang J, Zhao B, Chen X, Wang Z, Xu H, Huang B (2018) Silence of long noncoding RNA NEAT1 inhibits malignant biological behaviors and chemotherapy resistance in gastric cancer. Pathol Oncol Res 24(1):109–113
de Sousa Cavalcante L, Monteiro G (2014) Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol 741:8–16
Lorendeau D, Dury L, Nasr R, Boumendjel A, Teodori E, Gutschow M, Falson P, Di Pietro A, Baubichon-Cortay H (2017) MRP1-dependent collateral sensitivity of multidrug-resistant cancer cells: identifying selective modulators inducing cellular glutathione depletion. Curr Med Chem 24(12):1186–1213
Yan M, Wang J, Ren Y, Li L, He W, Zhang Y, Liu T, Li Z (2019) Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell Death Dis 10(3):204
Wang S, Meng Q, Xie Q, Zhang M (2017) Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. Mol Med Rep 15(3):1179–1187
Shang C, Ao CN, Cheong CC, Meng L (2019) Long non-coding RNA CDKN2B antisense RNA 1 gene contributes to paclitaxel resistance in endometrial carcinoma. Front Oncol 9:27
Shang C, Tang W, Pan C, Hu X, Hong Y (2018) Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma. Cancer Chemother Pharmacol 81(4):671–678
Cao W, Liu B, Ma H (2019) Long non-coding RNA GHET1 promotes viability, migration and invasion of glioma cell line U251 by down-regulation of miR-216a. Eur Rev Med Pharmacol Sci 23(4):1591–1599
Acknowledgements
This work was supported by the National Nature Science Foundation of China (Grant Nos. 81872067, 30901480, 81301834).
Author information
Authors and Affiliations
Contributions
ZL and DX carried out the experiments and performed the statistical analysis. HZ participated in the study design and drafted the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflicts of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Li, B., Xie, D. & Zhang, H. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer. Cancer Chemother Pharmacol 84, 187–194 (2019). https://doi.org/10.1007/s00280-019-03873-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-019-03873-8